Syndax Pharmaceuticals

Syndax Pharmaceuticals

Biotechnology Research

Waltham, MA 19,194 followers

Über uns

Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. Syndax corporate headquarters are in Waltham, MA.

Website
http://www.syndax.com
Industrie
Biotechnology Research
Größe des Unternehmens
51-200 Mitarbeiter
Hauptsitz
Waltham, MA
Typ
Öffentliches Unternehmen

Standorte

Employees at Syndax Pharmaceuticals

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

Syndax Pharmaceuticals 15 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 230.0M

Siehe mehr Informationen auf crunchbase